---
title: "Passage Bio (PASG) news: reverse merger"
url: "https://aibio.space/companies/passage-bio/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "PASG reverse merger news: Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5. Passage Bio, Inc. (NASDAQ: PASG), United States."
---

PASG Passage Bio, Inc. NASDAQ · United States

# Passage Bio (PASG) news PASG reverse merger news

Mergers · 2026-10-09

## [Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5](https://aibio.space/news/passage-bio-holders-would-keep-about-6-percent-remix-reverse-merger/)

The amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9.

## Latest Passage Bio news

1. 2025-07-29 Listings [Passage Bio regains compliance with Nasdaq minimum bid price rule](https://aibio.space/news/passage-bio-regains-compliance-nasdaq-minimum-bid-price-rule/) Nasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024.

## Passage Bio at a glance

- **Ticker**: PASG

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $24.2 million

### Related companies

- [Entrada Therapeutics](https://aibio.space/companies/entrada-therapeutics/) NASDAQ: TRDA
- [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) NASDAQ: PMVP
- [Regen Biopharma](https://aibio.space/companies/regen-biopharma/) OTC: RGBP
- [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU
- [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB
- [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA
- [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN
- [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE

### Also on NASDAQ

- [Adlai Nortye Group](https://aibio.space/companies/adlai-nortye/) ANL
- [Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON
- [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO
- [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) AVBP
- [Beyond Air](https://aibio.space/companies/beyond-air/) XAIR
- [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) RIGL

## Passage Bio annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$23.3 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) | [$40.2 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) |
| Net income (loss) | [-$45.5 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) | [-$64.8 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) |
| Cash from operations | [-$31.5 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) | [-$48.0 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) |
| Cash and equivalents | [$46.3 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926093021/) | [$37.6 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) |
| Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) | [$39.2 million](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.2 million, plus short-term investments of $0, $24.2 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Passage Bio

Is Passage Bio doing a reverse merger?

Our latest story on this, dated Oct 9, 2026: "Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/passage-bio-holders-would-keep-about-6-percent-remix-reverse-merger/).

What is the ticker symbol of Passage Bio?

Passage Bio, Inc. trades under the ticker PASG on NASDAQ.

Where is Passage Bio listed?

Passage Bio, Inc. is listed on NASDAQ.

What is the SEC CIK of Passage Bio?

The SEC Central Index Key (CIK) for Passage Bio, Inc. is 1787297. Its filings are on SEC EDGAR.

How many shares does Passage Bio have outstanding?

3,217,810 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10.

Which country or territory is Passage Bio listed under?

Our directory records Passage Bio, Inc. under United States.

What does Passage Bio do?

Our directory classifies Passage Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Passage Bio?

The ISIN recorded for Passage Bio, Inc. is US7027122099.

Does aibio.space cover Passage Bio?

aibio.space lists Passage Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Passage Bio incorporated?

SEC records list its state or country of incorporation as DE.

Is Passage Bio profitable?

Passage Bio, Inc. reported a net loss of $45.5 million for the fiscal year ended Dec 31, 2025, and used $31.5 million of cash in operations, per its annual report to the SEC.

How much does Passage Bio spend on research and development?

$23.3 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Passage Bio have?

$24.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is the latest Passage Bio (PASG) stock news?

Our latest story on Passage Bio, dated Oct 9, 2026: "Passage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5". The amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9. [Source](https://aibio.space/news/passage-bio-holders-would-keep-about-6-percent-remix-reverse-merger/).

Is Passage Bio at risk of delisting?

Our latest listing story, dated Jul 29, 2025: "Passage Bio regains compliance with Nasdaq minimum bid price rule". Nasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024. [Source](https://aibio.space/news/passage-bio-regains-compliance-nasdaq-minimum-bid-price-rule/).

## Investor discussion: Passage Bio

Members talk about Passage Bio (PASG). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Passage Bio, newest first. Each line links the filing it comes from.

1. 2026-06-24 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,3.02,5.01,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/tm2618476d1_ex99-1.htm)
2. 2026-05-27 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm)
3. 2026-05-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465926058987/pasg-20260331x10q.htm)
4. 2026-04-28 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465926049755/tm2612859d1_8k.htm)
5. 2026-03-10 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465926025550/tm268398d1_8k.htm)
6. 2025-11-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/pasg-20251110xex99d1.htm)
7. 2025-08-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/pasg-20250812xex99d1.htm)
8. 2025-07-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925071779/tm2521926d1_8k.htm)
9. 2025-07-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925067561/tm2520584d1_ex99-1.htm)
10. 2025-05-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925054907/tm2516589d1_8k.htm)
11. 2025-04-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787297/000155837025004877/pasg-20250528xdef14a.htm)
12. 2025-04-04 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1787297/000155837025004441/pasg-20250528xpre14a.htm)
13. 2025-03-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925020562/tm258210-1_424b5.htm)
14. 2025-01-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925008100/tm254971d1_8k.htm)
15. 2025-01-10 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,2.06,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1787297/000110465925002278/tm252728d1_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PASG on TradingView](https://www.tradingview.com/symbols/NASDAQ-PASG/).

## SEC filings and registration

- **SEC name**: Passage BIO, Inc.

- **CIK**: 1787297

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: PASG (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: ONE COMMERCE SQUARE, PHILADELPHIA, PA, 19103

- **Phone**: 2678660312

- **Shares outstanding**: 3,217,810 as of 2026-08-05 (10-Q filed 2026-08-10)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000114036126035515/ef20081513_8k.htm) filed 2026-09-03
- [10-Q](https://www.sec.gov/Archives/edgar/data/1787297/000110465926093021/pasg-20260630x10q.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/tm2618476d1_8k.htm) filed 2026-06-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm) filed 2026-05-27
- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000110465926065991/tm2615548d1_8k.htm) filed 2026-05-26
- [10-Q](https://www.sec.gov/Archives/edgar/data/1787297/000110465926058987/pasg-20260331x10q.htm) filed 2026-05-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000110465926049755/tm2612859d1_8k.htm) filed 2026-04-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1787297/000110465926045219/tm2612152d1_8k.htm) filed 2026-04-20

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001787297), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Passage Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PASG, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Passage Bio, Inc.

- **Ticker**: PASG

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US7027122099

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PASG/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/passage-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Passage Bio (PASG) news: reverse merger", 2026-10-31, https://aibio.space/companies/passage-bio/